0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 18, 2025 22:51 ET (02:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。
没有相关数据
如果下载按钮点击无跳转,请点击右上角菜单选择 “在浏览器打开”